Not every fish-oil bottle is designed with dry eye in mind. Some provide only a few hundred milligrams of EPA and DHA, some emphasize DHA rather than EPA, and others do not identify the chemical form of the oil. PRN De3 Dry Eye Omega Benefits stands out because its dose, ratio, rTG form and dry-eye-specific clinical history point toward a very specific use case.

This U.S. guide explains what is inside PRN De3, why it is frequently recommended by eye-care professionals, what the research says, and how the EyePromise name transition relates to the PRN-branded product currently sold on EyeDropShop.

What is PRN De3 Dry Eye Omega Benefits?

PRN De3 is a dietary supplement for adults. Rather than coating the ocular surface like an eye drop, it supplies long-chain omega-3 fatty acids and vitamin D3 systemically.

The current product page recommends three gelcaps daily. That serving supplies the following:

The total labelled EPA plus DHA is 2,240 mg per day. The formula also contains additional omega-3 fatty acids, with fish oil sourced from species such as anchovy, sardine and mackerel. The capsules contain bovine gelatin and a soy-derived mixed tocopherol, so the product is not vegetarian and may not suit every allergy profile.

Why is PRN De3 considered a top dry-eye omega?

“Top” should mean more than expensive packaging or a large fish-oil number on the front label. A serious comparison should examine the amount of EPA and DHA—not merely total fish oil—the ratio between them, the oil form, the serving burden, manufacturing and testing information, and how closely the product matches the formula used in published research.

PRN De3 performs strongly on that checklist:

• High active dose: 2,240 mg of EPA plus DHA in three capsules.
• Deliberate 3:1 EPA:DHA ratio: a high-EPA profile rather than a general wellness blend.
• Re-esterified triglyceride form: a form that has shown stronger long-term incorporation than ethyl esters in some comparative research.
• Vitamin D3 included: 1,000 IU per daily serving.
• Formula-specific clinical history: the 1,680 mg EPA/560 mg DHA rTG composition has been used in randomized dry-eye trials, including both positive and negative results.
• Quality positioning: the U.S. listing describes Norwegian manufacturing, cGMP facilities, molecular distillation and third-party purity testing.
• Three-softgel routine: 90-, 180- and 270-softgel sizes provide roughly 30, 60 and 90 days.

That combination makes PRN De3 one of the most complete dry-eye omega formulas available on EyeDropShop. It does not mean that every person will respond, that it replaces an eye exam, or that a less expensive formula cannot be appropriate. For a closer look at the numbers, read why PRN De3 uses a 3:1 EPA:DHA ratio.

How do you read the current U.S. bottle?

Start with the full serving, not the amount in one softgel. The front label states three softgels a day; the product details list 1,680 mg EPA, 560 mg DHA and 1,000 IU vitamin D3 in that daily serving. The bottle is sold in 90-, 180- and 270-softgel sizes, which work out to roughly 30, 60 and 90 days.

Then check the ingredient and allergy information. The current U.S. listing names fish oils from anchovies, sardines and mackerel, bovine gelatin and soy-derived mixed tocopherols. Packaging can change, so use the Supplement Facts and ingredient panel on the bottle you receive as the final reference.

What is rTG omega-3?

Concentrated fish oil is often converted into an ethyl ester form during processing. In an rTG product, the fatty acids are reattached to a glycerol backbone after concentration and purification. The result is a re-esterified triglyceride structure.

A six-month randomized comparison found a larger rise in the omega-3 index with re-esterified triglycerides than with an equal dose in ethyl ester form. That supports the practical importance of form, but it does not establish a universal “three times better” rule for every product, meal and person. Bioavailability varies with formulation and whether capsules are taken with food containing fat.

What do clinical trials show?

The evidence deserves a balanced answer. A 2016 randomized trial studied the same 1,680 mg EPA and 560 mg DHA rTG dose in people with dry eye related to meibomian gland dysfunction. After 12 weeks, the omega-3 group improved more than safflower-oil control on tear osmolarity, tear break-up time, OSDI scores and MMP-9.

However, the large 2018 DREAM trial tested a different omega-3 regimen—2,000 mg EPA and 1,000 mg DHA in ethyl ester form—and found no meaningful advantage over an olive-oil placebo after one year. More recently, a 2024 randomized trial using De3 at 1,680 mg EPA and 560 mg DHA did not find a symptom advantage over grapeseed oil after 12 weeks in a smaller MGD population.

Meanwhile, a 2023 meta-analysis of randomized trials reported overall improvements and found that higher dose, longer duration and higher EPA percentage were associated with greater symptom reduction. The studies differed greatly in formulation, populations and controls, which is one reason conclusions remain inconsistent.

How long should you try it?

Omega-3 supplements are not fast-acting lubricating drops. The current directions recommend daily, consistent use, and the brand advises allowing about 90 days to evaluate a response. Taking it sporadically for a week is unlikely to be a useful test.

Use the full labelled serving unless a healthcare professional advises otherwise, take it with a meal, and track symptoms using the same questions over time: burning, grittiness, end-of-day comfort, contact-lens tolerance and reliance on rescue drops. Our PRN De3 dosage and safety guide explains how to run a sensible 90-day trial.

Who should ask a healthcare professional first?

Ask before starting if you take anticoagulant or antiplatelet medication, have a bleeding disorder, are preparing for surgery, are pregnant or breastfeeding, have a fish or soy allergy, take other vitamin D products or have a condition affected by vitamin D or calcium. The U.S. product page specifically advises consulting a physician before using oral supplements, especially with blood thinners.

New pain, significant redness, discharge, injury, light sensitivity or a sudden change in vision should be assessed rather than managed with a supplement trial.

Is PRN De3 becoming EyePromise De3?

EyePromise now markets De3 under EyePromise branding on its own U.S. site. EyeDropShop.com, however, still lists and ships the current PRN-branded U.S. bottle at the time of writing.

Existing PRN customers do not need to switch simply because another site shows different branding. See the full PRN De3 and EyePromise De3 guide for the details to check.

Frequently asked questions

Is PRN De3 a medication?

No. It is a dietary supplement. It should complement—not replace—diagnosis and a complete dry-eye plan.

Is 2,400 mg the same as EPA plus DHA?

No. The U.S. label lists 2,400 mg total omega-3 fatty acids, while EPA plus DHA equals 2,240 mg: 1,680 mg EPA plus 560 mg DHA.

Can I take fewer than three softgels?

Three daily is the labelled serving and the amount that delivers the stated formula. Ask your healthcare professional before changing it.

Does it replace warm compresses or eye drops?

No. Dry eye is multifactorial. Omega-3 may be one part of a plan that also addresses eyelids, meibomian glands, tear replacement, environment and prescription treatment when needed.

Sources

• EyeDropShop U.S.: current PRN De3 product page
• EyePromise: De3 Omega Benefits
• Epitropoulos et al., 2016
• DREAM Research Group, 2018
• JAMA Ophthalmology randomized trial, 2024
• Wang and Ko meta-analysis, 2023
• Neubronner et al.: rTG versus ethyl ester incorporation

This article is educational and does not replace advice from an optometrist, ophthalmologist, pharmacist or physician. Dietary supplement statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent disease. Product formulas and packaging can change; check the current U.S. label.